| 发明名称 | Respiratory disease treatment | ||
| 摘要 | There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit. | ||
| 申请公布号 | US8815837(B2) | 申请公布日期 | 2014.08.26 |
| 申请号 | US201213537503 | 申请日期 | 2012.06.29 |
| 申请人 | Pulmagen Therapeutics (Inflammation) Limited | 发明人 | Finch Harry;Fox Craig;Sajad Mohammed;Bondil Van Niel Monique;Forrest Andrew |
| 分类号 | A01N43/00 | 主分类号 | A01N43/00 |
| 代理机构 | Morgan, Lewis & Bockius LLP | 代理人 | Morgan, Lewis & Bockius LLP |
| 主权项 | 1. A dry powder pharmaceutical composition adapted for pulmonary administration by inhalation, the composition comprising: a glitazone, and one or more pharmaceutically acceptable carriers and/or excipients,wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, andwherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof. | ||
| 地址 | Buckinghamshire GB | ||